Heterogeneity of hepatocellular carcinoma that responds differently to combination therapy with TACE and Sorafenib as determined by digital spatial gene expression profiling.

Chenhao XuRenyi SuZhengyang LuYisu SongXiaobing ZhangWenzhi ShuZhe YangRunzhou ZhuangXiao XuXuyong Wei

Published in: Genes & genomics (2024)

TAM infiltration may play a key role. Meanwhile, the introduction of immunotherapy in patients resistant to combination therapy may lead to positive results.

Keyphrases

combination therapy
end stage renal disease
genome wide
newly diagnosed
ejection fraction
prognostic factors
single cell
copy number
genome wide identification
patient reported outcomes
patient reported